Jonathan Young

Chief Operating Officer

Jonathan Young (Chief Operating Officer) filed 8 Form 4 reports in the past 24 months (0 purchases, 8 sales), most often in AKRO. The largest single filing was $2.2M of AKRO (50,000 sh across 2 lots, as filed), executed Mar 4 2025. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 8 sells

Median delay

–

measured on stock purchases

Volume, ttmiDollar value disclosed in the trailing twelve months

$5.2M

shares × price, as filed

Last traded

Oct 1 2025

Filed Oct 3 2025

Open performance→

Volume by month

Buys $0 Sells $5.2M

Shares × price, as filed · by filing month · past 24 months

Most traded names

AKRO AKRO 0 buys · 8 sells 8 filings

Recent filings

AKROSALE Akero Therapeutics, Inc. View filing → $597K
12,500 sh across 2 lots
Exec Oct 1 2025
Filed Oct 3 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $573K
12,439 sh across 2 lots
Exec Sep 2 2025
Filed Sep 4 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $532K
11,151 sh × $47.72
Exec Aug 12 2025
Filed Aug 13 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $135K
2,493 sh × $53.99
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $2.2M
50,000 sh across 2 lots
Exec Mar 4 2025
Filed Mar 5 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $538K
10,000 sh across 2 lots
Exec Feb 3 2025
Filed Feb 5 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $280K
10,000 sh × $28.03
Exec Jan 2 2025
Filed Jan 6 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $321K
10,000 sh × $32.13
Exec Dec 2 2024
Filed Dec 4 2024 · 5:30 PM ET More filings →